Limitations in current clinical trials on renal denervation

Wang, Yutang (2014) Limitations in current clinical trials on renal denervation. International Journal of Cardiology, 174 (1). 225 -225.

[img]
Preview
PDF (Author Accepted Version) - Accepted Version
Download (138kB) | Preview
[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website: http://dx.doi.org/10.1016/j.ijcard.2014....
 
3
21


Abstract

[Extract] Renal denervation (RDN) has become a standard treatment option to lower blood pressure (BP) in patients with resistant hypertension in many countries since 2010. There is a huge interest in investigating the effect of RDN on resistant hypertension and other diseases (e.g. diabetes and heart failure), and 118 clinical trials have been registered at ClinicalTrials.gov. A large number of early clinical trials demonstrate that RDN lowers blood pressure. However, on 9 January 2014, Medtronic reported that RDN did not lower blood pressure in the randomized and sham controlled Symplicity HTN-3 trial.

Item ID: 34890
Item Type: Article (Commentary)
ISSN: 1874-1754
Date Deposited: 26 May 2015 03:58
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110201 Cardiology (incl Cardiovascular Diseases) @ 100%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920101 Blood Disorders @ 0%
92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920102 Cancer and Related Disorders @ 0%
92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100%
Downloads: Total: 21
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page